Edwards Lifesciences Corporation $EW Shares Newly Purchased by WoodTrust Financial Corp

WoodTrust Financial Corp bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,480 shares of the medical research company’s stock, valued at approximately $904,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Bank of America Corp DE bought a new position in Edwards Lifesciences during the 2nd quarter valued at $605,397,000. Deutsche Bank AG bought a new position in Edwards Lifesciences during the 2nd quarter valued at $516,552,000. Finally, Legal & General Group Plc purchased a new position in Edwards Lifesciences during the 2nd quarter worth $389,089,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.33 during midday trading on Friday, reaching $83.91. The company had a trading volume of 1,555,942 shares, compared to its average volume of 4,508,433. The stock has a market cap of $48.31 billion, a P/E ratio of 48.13, a P/E/G ratio of 2.25 and a beta of 0.87. The company’s 50 day moving average price is $88.74 and its 200 day moving average price is $86.17. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. Citigroup reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Monday. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, September 26th. Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Piper Sandler reissued an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Truist Financial boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.